Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease GlobeNewswire - Wed Dec 17, 6:00AM CST

Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2  Durable CFTR transgene expression within target...

FDMT : 8.68 (-0.12%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Dec 12, 3:05PM CST

EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Dec 8, 7:00AM CST

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward GlobeNewswire - Thu Nov 20, 7:00PM CST

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The...

FDMT : 8.68 (-0.12%)
NBP : 4.19 (+5.81%)
AURA : 5.86 (+1.38%)
4DMT to Participate in 8th Annual Evercore Healthcare Conference GlobeNewswire - Thu Nov 20, 7:00AM CST

EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
4DMT Appoints Kristian Humer as Chief Financial Officer GlobeNewswire - Mon Nov 17, 5:00AM CST

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
4DMT Announces New Employment Inducement Grants GlobeNewswire - Fri Nov 14, 3:05PM CST

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones GlobeNewswire - Mon Nov 10, 7:00AM CST

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive...

FDMT : 8.68 (-0.12%)
4DMT to Participate in Jefferies 2025 London Healthcare Conference GlobeNewswire - Thu Nov 6, 3:05PM CST

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Thu Nov 6, 5:23AM CST

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 8.68 (-0.12%)

Barchart Exclusives

The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside Barchart - Sat Dec 20, 11:00AM CST
These biotech bets are only for investors who can stomach volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot